

Paraneoplastic Autonomic Disorders

Steven Vernino MD PhD FAAN FAAS

Professor of Neurology, UT Southwestern

Rex Griswold Distinguished Professor in Multiple System Atrophy

Dr. Bob and Jean Smith Foundation Distinguished Chair in

Neuromuscular Disease Research

Past president, American Autonomic Society

Disclosures

Dr. Vernino has served as consultant for argenx, Alterity, Antag, LabCorp, CSL Behring

Research support from NIH, Dysautonomia International, Sjogren's Foundation, Grifols, Takeda, BioHaven and Quest/Athena Diagnostics

Learning Objectives

- Review the concept and pathophysiology of Paraneoplastic neurological disorders
- Recognize the clinical presentations of Paraneoplastic autonomic disorders
- Understand the implication of neurological autoantibody results
- Be aware of other autoimmune/paraneoplastic disorders with autonomic features

Summary

- Neurological autoimmunity may occur in the context of cancer and may be precipitated by immune checkpoint inhibitor therapy
- Autonomic disorders (especially GI dysmotility) are common paraneoplastic neurological syndromes
- Paraneoplastic autonomic issues may be underrecognized
- Autoantibody testing can assist with diagnosis

References

- Blackburn KM, Kubiliun M, Harris S, Vernino S. Neurological autoimmune disorders with prominent gastrointestinal manifestations: A review of presentation, evaluation, and treatment. *Neurogastroenterol Motil*. 2019;31(10):e13611.
- Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. *Neurology*. 1998;50(3):652-657.
- Vernino S. Autoimmune Autonomic Disorders. *Continuum (Minneap Minn)*. 2020;26(1):44-57.
- Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. *N Engl J Med*. 2003;349(16):1543-1554.